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Bradykinin (BK) and its receptors (B1 and B2 receptors) play important
roles in inflammatory nociception. However, the patterns of expression and
physiological/pathological functions of B1 and B2 receptors in trigeminal ganglion
(TG) neurons remain to be fully elucidated. We investigated the functional expression
of BK receptors in rat TG neurons. We observed intense immunoreactivity of B2
receptors in TG neurons, while B1 receptors showed weak immunoreactivity. Expression
of the B2 receptor colocalized with immunoreactivities against the pan-neuronal
marker, neurofilament H, substance P, isolectin B4, and tropomyosin receptor kinase
A antibodies. Both in the presence and absence of extracellular Ca2+ ([Ca2+]o),
BK application increased the concentration of intracellular free Ca2+ ([Ca2+]i). The
amplitudes of BK-induced [Ca2+]i increase in the absence of [Ca2+]o were significantly
smaller than those in the presence of Ca2+. In the absence of [Ca2+]o, BK-induced
[Ca2+]i increases were sensitive to B2 receptor antagonists, but not to a B1 receptor
antagonist. However, B1 receptor agonist, Lys-[Des-Arg9]BK, transiently increased
[Ca2+]i in primary cultured TG neurons, and these increases were sensitive to a B1
receptor antagonist in the presence of [Ca2+]o. These results indicated that B2 receptors
were constitutively expressed and their activation induced the mobilization of [Ca2+]i
from intracellular stores with partial Ca2+ influx by BK. Although constitutive B1 receptor
expression could not be clearly observed immunohistochemically in the TG cryosection,
cultured TG neurons functionally expressed B1 receptors, suggesting that both B1 and
B2 receptors involve pathological and physiological nociceptive functions.
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Introduction
Tissue damage results in an accumulation of endogenous chemical substances, such as
bradykinin (BK), which are released by nociceptive afferents and/or non-neural cells in the
injured area of the tissue (Julius and Basbaum, 2001; Basbaum et al., 2009). BK receptors,
which are divided into two subtypes (B1 and B2), are plasma membrane G-protein-coupled
receptors of the seven-transmembrane-domain family. The existence of B1 and B2 receptors
has been confirmed by pharmacological and radioligand-binding studies, as well as by mRNA
expression analyses, in a wide variety of cells (Hess et al., 1994; Pesquero et al., 1996; Hall, 1997).
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Previous studies have indicated that B2 receptors couple with the
Gq protein. Activation of the Gq protein activates phospholipase
C, which induces a number of intracellular second messenger
systems, including 1, 2-diacylglycerol and inositol 1, 4, 5-
trisphosphate, which activates protein kinase C and mobilizes
intracellular Ca2+, respectively (Walker et al., 1995; Tiwari et al.,
2005).
BK-induced changes in the chemical environment
surrounding axons cause peripheral sensitization, which is
associated with inflammatory responses (Basbaum et al.,
2009). Neuropathic pain is also involved in peripheral and
central sensitization, which increases chronic pain states
(Cervero and Laird, 1996; Scholz and Woolf, 2002; Ochoa,
2009). Injury to trigeminal ganglion (TG) neurons, which
occasionally induces neuropathic pain, has been reported to
be mediated by both B1 and B2 receptors in the orofacial
area. Formalin-induced orofacial pain responses in rats are
reduced by B2 receptor inhibition (Chichorro et al., 2004). In
addition, administration of B1 and B2 receptor antagonists
delays the development of thermal hyperalgesia in the orofacial
area, which is induced by constriction of the infraorbital
nerve in rats and mice (Luiz et al., 2010). Thus, the functional
role of BK receptors in TG neurons in physiological and
pathological nociception has been well described by behavioral
studies. However, the basic expression patterns of B1 and B2
receptors in TG neurons are still unclear and remain to be fully
elucidated.
In the present study, we investigated the expression and
localization, as well as physiological and pharmacological




All the animals used in our study were treated in accordance
with the Guiding Principles for the Care and Use of Animals
in the Field of Physiological Sciences, which was approved
by the Council of the Physiological Society of Japan and the
American Physiological Society. In addition, the study followed
the guidelines that were established by the National Institutes
of Health (USA) regarding the care and use of animals for
experimental procedures. This study was approved by the Animal
Research Ethics Committee of Tokyo Dental College (approval
No. 252502).
Cell Culture
TG cells were isolated from neonatal Wistar rats (7 days old)
(Kawaguchi et al., 2015) that were under pentobarbital sodium
anesthesia (50 mg/kg) following the administration of isoflurane
(3.0 Vol%). TG cells were dissociated by enzymatic treatment
with Hank’s balanced salt solution (Life Technologies, Grand
Island, NY, USA) containing 20 U/mL papain (Worthington
Biochemical Corporation, Lakewood, NJ, USA) for 20 min at
37◦C, which was followed by dissociation by trituration. After
dissociation, the TG cells were plated on 35 mm-diameter
dishes (Corning Incorporated Life Sciences, Tewksbury,
MA, USA) and cultured for 48 h at 37◦C (95% air and 5%
CO2). The primary cells were cultured in Leibovitz’s L-15
medium (Life Technologies) containing 10% fetal bovine
serum, 1% penicillin-streptomycin (Life Technologies),
1% fungizone (Life Technologies), 26 mM NaHCO3, and
30 mM glucose (pH 7.4). For the immunocytochemistry,
TG cells were subjected to primary culture on poly-L-lysine-
coated cover glasses (Matsunami Glass Ind., Ltd., Osaka,
Japan).
Immunofluorescence Analysis
TGs isolated from neonatal Wistar rats (7 days old) were fixed
in optimal cutting temperature compound and rapidly frozen
in liquid nitrogen. Frozen tissues were cut at a thickness of
10 µm and placed on slides. After fixation by 50% ethanol
and 50% acetone at −20◦C for 30 min, primary cultured
TG cells and cryosections were treated with 10% donkey
serum at room temperature for 20 min and then incubated
overnight at 4◦C with primary antibodies (Kuroda et al.,
2013). A cocktail of primary antibodies (Neuro-ChromTM Pan
Neuronal Marker, EMD Millipore, Billerica, MA, USA; 1:50
dilution), including mouse anti-Neuronal nuclei (NeuN), anti-
microtubule-associated protein 2 (MAP2), anti-βIII tubulin, and
anti-neurofilament H (NF-H) antibodies, was used as a neuronal
marker. TG cells were also incubated with either mouse anti-NF-
H (SantaCruz, CA, USA; 1:200 dilution) as an A-neuron marker,
mouse anti-substance P (SP; R&D Systems, Minneapolis, MN,
USA; 2.5 µg/100 µl dilution) as a peptidergic C-neuron marker,
FITC-conjugated anti-isolectin B4 (IB4; Vector laboratories, CA,
USA; 1:200 dilution) as a non-peptidergic C-neuron marker,
goat anti-high-affinity nerve growth factor (NGF) receptor (a
tropomyosin receptor kinase A (TrkA); R&D Systems; 1.5
µg/100 µl dilution) as an NGF-responsive nociceptor marker
(Mantyh et al., 2011), and rabbit anti-B1 receptor (Alomone
Labs, Jerusalem, Israel; 1:50 dilution) and rabbit anti-B2 receptor
(Alomone Labs; 1:50 dilution) (Duehrkop et al., 2013; Dutra
et al., 2013) antibodies. For negative controls, the sections were
incubated with non-immune IgGs (Abcam, Cambridge, UK;
1:50; N = 4 from four rats) (Figure 2M). The cells and tissues
were then washed and incubated with a secondary antibody
at room temperature for 30 min. The secondary antibodies
were Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 568
donkey anti-mouse IgG, Alexa Fluor 568 donkey anti-rabbit IgG,
and Alexa Fluor 568 donkey anti-goat IgG (1:50 dilution; Life
Technologies) for the fluorescence staining and 4′, 6-diamino 2-
phenylindole dihydrochloride (Life Technologies) for the nuclear
staining (room temperature for 5 min). The cells and tissues were
examined under fluorescence microscopes (Carl Zeiss AG, Jena,
Germany; Keyence Corporation, Osaka, Japan).
Solutions and Reagents
A standard solution containing (in mM) 137 NaCl, 5.0 KCl, 2.0
CaCl2, 0.5 MgCl2, 0.44 KH2PO4, 0.34 Na2HPO4, 4.17 NaHCO3,
and 5.55 glucose (pH 7.4) was used as an extracellular solution.
A high-K+ solution containing (in mM) 91 NaCl, 50 KCl, 2.0
CaCl2, 0.5 MgCl2, 0.44 KH2PO4, 0.34 Na2HPO4, 4.17 NaHCO3,
and 5.55 glucose (pH 7.4) was used to discern TG neurons from
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glial cells by activation of depolarization-induced increases in
intracellular free Ca2+ concentration ([Ca2+]i) in neurons. BK, a
selective B2 receptor antagonist (HOE140), a selective B1 receptor
antagonist (R715) and a highly selective B1 receptor agonist (Lys-
[Des-Arg9]BK) were obtained from Tocris Bioscience (Bristol,
UK). All the other reagents were purchased from Sigma-Aldrich
Co. LLC (St. Louis, MO, USA), except where indicated.
Measurement of [Ca2+]i
Primary cultured TG cells were loaded for 90 min at 37◦C
in Hank’s solution containing 10 µM of fura-2 acetoxymethyl
ester (Dojindo Laboratories, Kumamoto Japan) and 0.1% (w/v)
pluronic acid F-127 (Life Technologies). Cultured TG cells were
then rinsed with fresh Hank’s solution and mounted on a
microscope stage (Olympus Corporation, Tokyo, Japan). Fura-
2 fluorescence emission was measured at 510 nm in response
to alternating excitation wavelengths of 340 nm (F340) and
380 nm (F380) with an Aquacosmos system and software
(Hamamatsu Photonics K.K., Shizuoka, Japan), which controls
the excitation wavelength selector and intensified charge-coupled
device camera system (Hamamatsu Photonics K.K.). [Ca2+]i was
measured as the fluorescence ratio of F340 and F380 (RF340/F380)
and expressed as F/F0 units. The RF340/F380 value (F) was
normalized to the resting value (F0).
Statistical and Offline Analysis
The data were expressed as the mean ± standard error (S.E.)
or standard deviation of the mean of N observations, where
N represents the number of independent experiments or cells,
respectively. The Kruskal–Wallis test, Dunn’s posthoc test, or
Mann–WhitneyU-test was used to determine the nonparametric
statistical significance. P values less than 0.05 were considered
significant. The statistical analysis was performed with GraphPad
Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).
The dependence of the changes in [Ca2+]i on each
pharmacological agent was determined by fitting the data to








where K is the equilibrium binding constant, [x]o indicates the
applied concentration of the pharmacological agents, and F/F0int
and F/F0fin are the initial and final F/F0 responses, respectively.
Results
Immunolocalization of BK Receptors in TG
Neurons
The cultured TG neurons showed positive immunoreactivity
to a neuronal marker cocktail (Neuro-ChromTM pan-neuronal
marker), which contained mouse anti-NeuN, anti-MAP2, and
anti-βIII tubulin antibodies (Figures 1A,D). Intense B2 receptor
immunoreactivity was observed in primary cultured TG neurons
(Figure 1E), and it showed colocalization with the pan neuronal
marker (Figure 1F) in somata, dendrites, axons, and perinuclear
regions. Weak but positive B1 receptor immunoreactivity was
also observed in primary cultured TG cells (Figure 1B), and
the immunoreactivity colocalized with the pan neuronal marker
(Figure 1C).
In the TG cryosections, we could observe positive
immunoreactivity against the neuronal marker cocktail
(Figures 1G,J). These TG neurons in the cryosections
showed positive immunoreactivity to the B2 receptor antibody
(Figure 1K), showing colocalization with the pan neuronal
marker (Figure 1L) in somata, dendrites, axons, and perinuclear
regions. However, the TG cryosections did not show B1 receptor
immunoreactivity (Figures 1H,I). Positive immunoreactivity
was also observed with NF-H (an A-neuron marker; Figure 2A),
SP (a peptidergic C-neuron marker; Figure 2D), IB4 (a non-
peptidergic C-neuron marker; Figure 2G), and high-affinity
NGF receptor (TrkA; an NGF-responsive nociceptor marker;
Figure 2J) antibodies. These immunoreactivities against NF-H,
SP, IB4, and TrkA antibodies showed colocalization with those
against the B2 receptor antibodies (Figures 2B,C,E,F,H,I,K,L).
BK-Induced [Ca2+]i Increases in TG Neurons
We observed rapid and transient [Ca2+]i increases in TG
neurons following the administration of five different
concentrations of BK (0.01, 0.1, 1.0, 10, and 100 nM) in
the presence of external Ca2+ (2.0 mM; Figure 3A). A
semilogarithmic plot (Figure 3B) illustrates F/F0 values
as a function of the applied BK concentrations, and the
equilibrium-binding constant was the half-maximal 50%
effective concentration (EC50) of 1.0 nM.
HOE140, a B2 Receptor Antagonist, Inhibited the
BK-Induced [Ca2+]i Increases in TG Neurons
We examined the BK-induced [Ca2+]i responses in both the
presence and absence of external Ca2+. The application of BK
(1.0 nM) rapidly increased [Ca2+]i to a peak F/F0 value of 1.7
± 0.03 F/F0 units in the presence (2.0 mM) of external Ca2+
and 1.4 ± 0.03 F/F0 units in the absence (0 mM) of external
Ca2+ (Figures 4A,D). The amplitudes of the BK-induced [Ca2+]i
increases significantly differed between those in the presence
and absence of extracellular Ca2+. In the absence of extracellular
Ca2+, BK (1.0 nM)-induced [Ca2+]i increases were significantly
inhibited by a B2 receptor antagonist (100 nM of HOE140)
(Figures 4C,D) but not by a B1 receptor antagonist (1.0 µM of
R715) (Figures 4B,D).
The B1 Receptor Antagonist R715 did not Affect
the BK-Induced [Ca2+]i Increases
The BK-induced (1.0 nM) increases in [Ca2+]i were not
significantly inhibited in TG neurons by the administration
of four different concentrations of the B1 receptor antagonist
(0.001, 0.01, 0.1, and 1.0 µM of R715) in the presence (2.0 mM)
of external Ca2+ (Figures 5A,B).
Pharmacological Identification of B1 Receptors
in TG Neurons
We investigated the [Ca2+]i increases during the administration
of Lys-[Des-Arg9]BK, which is an endogenous, potent, and
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FIGURE 1 | Immunolocalization of B1 and B2 receptors in primary
cultured trigeminal ganglion (TG) neurons and TG cryosections.
(A,D,G,J) Cells positive for the pan neuronal marker in primary cultured
TG neurons (A,D) and TG cryosections (G,J). (B,H) Immunoreactivity to
the B1 receptor antibody (green) in primary cultured TG neurons (B) and
TG cryosections (H). (C,I) Triple immunofluorescence staining with
antibodies against the pan neuronal marker (red) and B1 receptor (green)
in primary cultured TG neurons (C) and TG cryosections (I). Nuclei are
shown in blue. (E,K) Positive immunoreactivity to the B2 receptor
antibody (green) in primary cultured TG neurons (E) and TG cryosections
(K). (F,L) Triple immunofluorescence staining with antibodies against the
pan neuronal marker (red) and B2 receptor (green) in primary cultured TG
neurons (F) and TG cryosections (L). Nuclei are shown in blue. Scale
bars are 50 µm in (A–F), and 20 µm in (G–L). Each set of images
showing representative immunolocalization of B1 (A–C) and B2 receptors
(D–F) in primary cultured TG neurons was obtained from six different
rats, while that showing immunolocalization of B1 (G–I) and B2 receptors
(J–L) in TG cryosections was obtained from five different rats.
highly selective B1 receptor agonist (Talbot et al., 2009; More
et al., 2014). The increases in [Ca2+]i in the TG neurons were
induced by the administration of five different concentrations of
Lys-[Des-Arg9]BK (0.01, 0.1, 1, 10, and 100 nM) in the presence
of extracellular Ca2+ (2.0 mM) (Figure 5C). A semilogarithmic
plot (Figure 5D) illustrates the F/F0 values as a function of the
applied concentration of Lys-[Des-Arg9]BKwith an equilibrium-
binding constant of 0.4 nM. In the presence of extracellular
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FIGURE 2 | Immunolocalization of B2 receptors in the soma of TG
neurons in cryosections. (A) Positive immunoreactivity to NF-H as an
A-neuron marker in TG neurons (arrowhead). (B,E,H,K) B2 receptor
immunoreactivity (arrowheads). (C) Triple immunofluorescence staining with
antibodies against B2 receptors (green) and NF-H (red). Nuclei are shown in
blue. (D) Positive immunoreactivity to SP as a peptidergic C-neuron marker in
TG neurons (arrowheads). (F) Triple staining with antibodies against B2
receptors (green) and SP (red). Nuclei are shown in blue. (G) Positive
immunoreactivity to IB4 as a non-peptidergic C-neuron marker in TG neurons
(arrowheads). (I) Triple staining with antibodies against B2 receptors (red) and
IB4 (green). Nuclei are shown in blue. (J) Positive immunoreactivity to TrkA as
an nerve growth factor (NGF)-responsive nociceptor marker in TG neurons
(arrowheads). (L) Triple staining with antibodies against B2 receptors (green)
(Continued)
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FIGURE 2 | Continued
and TrkA (red). Nuclei are shown in blue. (M) No fluorescence was detected in
the negative control. Scale bars: 20 µm. Each set of photos showing
representative colocalization of B2 receptors with NF-H (A–C) and SP (D–F)
was obtained from six different rats. Each set of photos showing
representative colocalization of B2 receptors with IB4 (G–I) and TrkA (J–L)
was obtained from four different rats.
Ca2+, the Lys-[Des-Arg9]BK-induced increase in [Ca2+]i was
significantly inhibited by a B1 receptor antagonist (1.0 µM of
R715) (Figures 5E,F).
Discussion
The present study demonstrated the functional expression
of BK receptors (B1 and B2) in TG neurons. B2 receptors
were present on axons and dendrites in A-neurons, non-
peptidergic C-neurons, peptidergic C-neurons, and NGF-
responsive nociceptors. While the localization pattern of the
B1 receptor was not clear in the TG cryosections, weak
immunoreactivity for B1 receptors was observed in the primary
cultured TG neurons. The application of BK activated B2
receptors and Lys-[Des-Arg9]BK activated the B1 receptors.
B2 receptor activation mobilized [Ca2+]i by releasing Ca2+
from internal Ca2+ stores with partial Ca2+ influx from the
extracellular medium.
B2 receptors, which are expressed ubiquitously and
constitutively in healthy tissues, are essential in the early
stages of general pain generation (Hall, 1992). The constitutive
expression of B2 receptors in TG neurons has been studied
by reverse transcription-polymerase chain reaction (RT-PCR)
analyses (Ceruti et al., 2011) and immunocytochemical analyses
in cultured TG neurons (Patwardhan et al., 2005). Although
BK-induced [Ca2+]i increases have also been reported in
TG neurons (Ceruti et al., 2008, 2011), precise functional
expression patterns of B1 and B2 receptors in TG neurons
remained unclear. The results of the present study showing
the functional expression and localization of B2 receptors
in TG neurons were in line with the previous results. The
results of this study were also in line with the pharmacological
properties of BK, which is a potent and endogenous agonist for
B2 receptors and not B1 receptors in the sympathetic neurons
of the rat superior cervical ganglion (Babbedge et al., 1995)
and in Chinese hamster ovary (CHO) cells stably expressing
recombinant human B1 or B2 receptors (Simpson et al., 2000).
Furthermore, BK has an affinity for B2 receptors that is 500
times that for B1 receptors (Simpson et al., 2000). Therefore,
B2 receptors are histologically and functionally expressed, and
endogenous BK preferentially activates B2 receptors in rat TG
neurons.
The expression of the B1 receptor, which is induced as
a result of tissue damage and inflammation, is involved
in chronic inflammation or tissue injury (Hall, 1992). The
observations of the constitutive B1 receptor expression in TG
and dorsal root ganglion (DRG) neurons have been inconsistent.
In DRG neurons, some immunohistochemical studies have
reported constitutive B1 receptor expression (Ma et al., 2000;
Wotherspoon and Winter, 2000). In contrast, other studies have
described that B1 receptor activation-induced [Ca2+]i responses
could not be observed in DRG neurons (Brand et al., 2001).
In TG neurons, an immunohistochemical study has shown the
constitutive expression of B1 receptors (Ma et al., 2000). In
contrast, RT-PCR analyses have demonstrated that B1 receptor
mRNA was barely expressed in intact tissue, while it was weakly
FIGURE 3 | Ca2+ dependence of extracellular bradykinin (BK)-induced
[Ca2+]i responses in TG neurons. (A) Examples of transient [Ca2+]i
increases following the application of a series of BK concentrations. In the
presence of extracellular Ca2+ (2.0 mM; lower white box), the application of
BK induced transient [Ca2+]i increases in a concentration-dependent manner.
The concentrations of BK (0.01–100 nM) that were administered are shown
in the uppermost white boxes. (B) The data points illustrate the F/F0 values
as a function of the applied BK concentration. Each data point represents
the mean ± standard error (S.E.) of seven experiments (the numbers in
parentheses represent the number of tested cells). The curve on the
semilogarithmic scale was fitted according to Equation 1, which is described
in the text. The upper gray box in (A) indicates the timing of the application
of the 50 mM KCl solution. The equilibrium binding constant of BK was
1.0 nM.
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FIGURE 4 | Pharmacological identification of BK receptors in TG
neurons. (A) Examples of transient [Ca2+]i increases following the
administration of 1.0 nM of BK (upper white boxes) with (lower gray
boxes) or without (lower white box) extracellular Ca2+ (2.0 mM). (B)
Examples of BK-induced (1.0 nM; upper white boxes) [Ca2+]i
increases with (upper black box) or without R715 in the absence
(lower white box) or presence (lower gray boxes) of external Ca2+.
(C) Examples of BK-induced (1.0 nM; upper white boxes) [Ca2+]i
increases with (upper black box) or without HOE140 in the absence
(lower white box) or presence (lower gray boxes) of external Ca2+.
(A,B,C) The upper gray boxes indicate the timing of the application
of the 50 mM of KCl solution. (D) The summary bar graph indicates
[Ca2+]i increases during the first (upper column) and second (second
upper column) application of 1.0 nM of BK with external Ca2+
(2.0 mM) (gray boxes on the right side). The mean values of the
increase in [Ca2+]i following the first (third upper column) and second
(fourth upper column) application of 1.0 nM of BK in the absence of
external Ca2+ as well as the application of 1.0 nM of BK with
1.0 µM of R715 (fifth upper column) and 100 nM of HOE140 (sixth
upper column) in the absence of external Ca2+ (white boxes on the
right side) are shown. Each column denotes the mean ± S.E. of the
indicated (in parentheses) number of experiments. The statistical
significance between the columns (shown by solid lines) is indicated
by asterisks: *p < 0.05.
expressed in primary cultured TG neurons. In primary cultured
TG neurons, the levels of expression of B1 receptor mRNA
have been reported to depend on the length of the culture
period (Ceruti et al., 2011). The present immunohistochemical
and immunocytochemical results were similar to the previous
RT-PCR results; B1 receptor immunoreactivity was weakly
positive in cultured TG neurons and could not be detected
in intact TG tissue. Although few report concerning B1
receptor-induced [Ca2+]i response in TG neurons exist, in the
[Ca2+]i imaging in the present study, the B1 receptor agonist,
Lys-[Des-Arg9]BK which is a metabolite of endogenous BK
in peripheral tissues (Regoli et al., 2001), dose-dependently
increased [Ca2+]i in the presence of extracellular Ca2+, and this
increase was suppressed by a B1 receptor-specific antagonist
(Figures 5C–F). These results of B1 receptor expression in
primary cultured TG neurons suggest that the expression of
B1 receptors is induced in TG neurons by tissue damage
and/or inflammation. However, further studies are required to
evaluate the expression patterns of B1 receptors in native TG
neurons.
BK-induced [Ca2+]i increases were observed in both the
presence and absence of extracellular Ca2+. However, the
amplitudes of the [Ca2+]i increases in the absence of extracellular
Ca2+ were significantly smaller (84.9 ± 11.3%, N = 161)
than those in the presence of Ca2+ (100%; Figures 4A,D).
This indicated that the BK-induced [Ca2+]i mobilization
(by B2 receptor activation) was mainly composed of Ca2+
release from internal stores with partial Ca2+ influx from
the extracellular medium. Notably, BK has been reported to
activate voltage-dependent Ca2+ channels in rat submucosal
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FIGURE 5 | Pharmacological identification of B1 receptors in TG
neurons. (A) Examples of BK-induced (1.0 nM; upper white boxes)
[Ca2+]i increases showing insensitivity to R715 (0.001–1.0 µM; upper
black boxes) in the presence of external Ca2+ (2.0 mM; lower white
box). (B) The summary bar graph indicates [Ca2+]i increases following
the first (upper column) application of 1.0 nM of BK with external Ca2+
(2.0 mM). The mean values for the increases in [Ca2+]i following the
application of 1.0 nM of BK with 0.001 µM (second upper column),
0.01 µM (third upper column), 0.1 µM (fourth upper column), or 1.0 µM
(fifth upper column) of R715 in the presence of external Ca2+ (white
boxes on the right side) are shown. Each column denotes the mean ±
S.E. of the indicated (in parentheses) number of experiments. There is no
statistical significance between the columns. (C) Examples of transient
[Ca2+]i increases following the application of a series of concentrations of
Lys-[Des-Arg9]BK (0.01–100 nM; upper white boxes) in the presence of
extracellular Ca2+ (2.0 mM; lower white box). (D) The data points
illustrate the F/F0 values as a function of the applied concentrations of
Lys-[Des-Arg9]BK. Each data point represents the mean ± S.E. of six
independent experiments (the numbers in parentheses represent the
number of tested cells). The curve on the semilogarithmic scale was
fitted according to Equation 1, which is described in the text. The
equilibrium-binding constant for Lys-[Des-Arg9]BK was 0.4 nM.
(E) Examples of Lys-[Des-Arg9]BK-induced (10 nM; upper white boxes)
[Ca2+]i increases that were significantly inhibited by 1.0 µM of R715
(upper black box) in the presence of external Ca2+ (2.0 mM; lower white
box). (A,C,E) The application of 50 mM of the KCl solution is shown in
the gray boxes. (F) Summary bar graph of the [Ca2+]i increases following
10 nM of Lys-[Des-Arg9]BK with (lower black column) or without (upper
white column) 1.0 µM of R715. Each column denotes the mean ± S.E.
of the indicated number (in parentheses) of independent experiments. The
statistical significance between the columns (shown by solid lines) is
indicated by asterisks: *p < 0.05.
plexus neurons (Avemary and Diener, 2010; Rehn et al., 2013),
and transient receptor potential cation channel subfamily-V
member-1 channels in rat DRG neurons (Ferreira et al., 2004;
Mistry et al., 2014). However, BK-induced Ca2+ currents could
not be recorded in TG neurons (Kitakoga and Kuba, 1993).
Although further studies are needed to clarify which Ca2+
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influx pathways contribute to the BK-induced Ca2+ influx
in TG neurons, the present results clearly indicate that BK
mobilizes [Ca2+]i through both intracellular Ca2+ release and
Ca2+ influx.
In addition, NGF-TrkA signaling plays important roles
in not only the developmental processes of peptidergic
nociceptive afferents, but also in the generation of acute
and chronic pain state in adults. The signaling also up-
regulates B2 receptor expression in peptidergic nociceptors
(Mantyh et al., 2011). Thus, the results showing colocalization
of B2 receptor and TrkA immunoreactivity in TG neurons
strongly support reports describing that the B2 receptor
mediates inflammatory/neuropathic pain induced by
peripheral sensitization in the orofacial region (Chichorro
et al., 2004; Luiz et al., 2010); however, the present results
obtained from neonatal rat may not reflect the situation in
adults.
In conclusion, B2 receptors were expressed constitutively,
and their activation induced the mobilization of [Ca2+]i
by releasing Ca2+ from intracellular stores with partial
Ca2+ influx. In contrast, B1 receptor expression was faint
in cultured TG neurons and absent in neurons in TG
cryosections, although a metabolite of endogenous BK
elicited [Ca2+]i increases. These results indicated that
both BK and its metabolites activated [Ca2+]i mobilization
in TG neurons through B2 and B1 receptor activation,
respectively.
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